Bio-Rad director exercises RSUs, gets new grant

Bio-Rad Laboratories director Melinda Litherland reported routine equity compensation activity.

Rhea-AI Filing Summary

Bio-Rad Laboratories director Melinda Litherland reported routine equity compensation activity. She exercised 407 restricted stock units into 407 shares of Bio-Rad Class A common stock, bringing her direct common stock holdings to 715 shares.

On the same date, she received a new grant of 369 restricted stock units, each representing a right to one share of Class A common stock. These new units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of stockholders, aligning her compensation with future company performance and governance milestones.

Insider Trade Summary

407 shares exercised/converted

Exercise 3 txns

Insider PEI MELINDA LITHERLAND

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	369	$0.00	$0.00
Exercise	Restricted Stock Units	407	$0.00	$0.00
Exercise	Bio-Rad A Common Stock	407	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 369 contracts (Direct); Bio-Rad A Common Stock — 715 shares (Direct)

Footnotes (3)

1. F1. Shares of Class A common stock acquired on the vesting of restricted stock units.
2. F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
3. F3. The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.

Key Figures

RSUs exercised: 407 units Shares held after exercise: 715 shares New RSU grant: 369 units +2 more

5 metrics

RSUs exercised 407 units Converted into 407 shares of Bio-Rad Class A common stock

Shares held after exercise 715 shares Director’s direct Class A common stock holdings following transactions

New RSU grant 369 units Each unit represents a right to one share of Class A common stock

RSU vesting trigger 100% cliff vesting Earlier of first anniversary of grant or next annual stockholders’ meeting

Transaction price per unit $0.00 Both RSU exercise and new RSU grant reported at zero price per unit

Key Terms

Restricted Stock Units, Each restricted stock unit represents a contingent right, Exercise or conversion of derivative security, Grant, award, or other acquisition, +1 more

5 terms

Restricted Stock Units financial

"Shares of Class A common stock acquired on the vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Each restricted stock unit represents a contingent right financial

"Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock."

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

will vest 100% on the earlier of the first anniversary financial

"The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BIO director Melinda Litherland report on this Form 4?

Melinda Litherland reported exercising 407 restricted stock units into 407 shares of Bio-Rad Class A common stock and receiving a new award of 369 restricted stock units. These transactions reflect routine equity compensation rather than open-market buying or selling activity.

How many Bio-Rad (BIO) shares does Melinda Litherland hold after the reported transactions?

After exercising restricted stock units, Melinda Litherland directly holds 715 shares of Bio-Rad Class A common stock. This total reflects the conversion of 407 previously granted restricted stock units into shares on the transaction date disclosed in the Form 4.

What new restricted stock unit grant did BIO’s Melinda Litherland receive?

Melinda Litherland received a grant of 369 restricted stock units, each representing a contingent right to one share of Bio-Rad Class A common stock. This grant increases her unvested equity-based compensation tied to the company’s future performance and governance events.

When will Melinda Litherland’s new BIO restricted stock units vest?

The 369 restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of Bio-Rad’s next annual meeting of stockholders. This vesting schedule links her equity compensation to a clear future corporate governance milestone.

Were Melinda Litherland’s BIO transactions open-market buys or sells?

The reported transactions were not open-market buys or sells. They involved exercising 407 restricted stock units into common shares and receiving a new grant of 369 restricted stock units, both at a transaction price per unit of $0.00 as compensation awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 03:25 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PEI MELINDA LITHERLAND

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CALIFORNIA 94547

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	04/21/2026		M		407(1)	A	$0	715	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	04/21/2026		A		369		(3)	(3)	Bio-Rad A Common Stock	369	$0	369	D
Restricted Stock Units	$0(2)	04/21/2026		M			407	(3)	(3)	Bio-Rad A Common Stock	407	$0	0	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.

Remarks:

	/s/ Melinda Litherland	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)